Table 4.
Variables independently related to adverse events in the total study populations (368 patients): Cox proportional hazard univariate and multivariate analysis
| Variables | Values of patients with vs without events | HR univariate analysis | CI | p | HR multivariate analysis | CI | p |
|---|---|---|---|---|---|---|---|
| LV ejection fraction (%) | 44 ± 14 vs 52 ± 13 | 0.96 | 0.95-0.98 | &0.001 | 0.98 | 0.96-0.99 | 0.003 |
| History of heart failure (%) | 87 vs 66 | 1.65 | 1.28-2.13 | &0.001 | 2.25 | 1.16-4.34 | 0.02 |
| GFR (ml/min/1.73/m2) | 43 ± 24 vs 63 ± 27 | 0.98 | 0.97-0.99 | &0.001 | 0.98 | 0.97-0.99 | 0.01 |
| Absolute contraindication to AVR (%) | 57 vs 27 | 3.58 | 2.16-5.94 | &0.001 | 2.39 | 1.35-4.22 | 0.003 |
| Treatment assignment for AS | - | 2.01 | 1.62-2.62 | &0.001 | 1.82 | 1.10-3.25 | &0.001 |
| Age (year) | 83 ± 8 vs 77 ± 9 | 1.02 | 1.01-1.03 | 0.004 | 1.05 | 0.99-1.09 | 0.07 |
| NYHA functional class (1–4) | 2.8 ± 0.7 vs 2.5 ± 0.07 | 2.02 | 1.41-2.90 | &0.001 | 1.05 | 0.81-1.36 | 0.69 |
| Charlons co-morbidity index | 3.9 ± 1.7 vs 2.7 ± 1.8 | 1.29 | 1.18-1.42 | &0.001 | 1.25 | 0.90-1.57 | 0.60 |
| Katz score | 4.1 ± 1.8 vs 3.1 ± 1.9 | 1.33 | 1.11-1.55 | &0.001 | 1.31 | 0.85-1.62 | 0.52 |
| Aortic valve area (cm2/m2) | 0.61 ± 0.18 vs 0.69 ± 0.20 | 1.44 | 0.45-4.41 | 0.52 | 0.18 | 0.01-2.82 | 0.22 |
| Peripheral artery disease (%) | 10 vs 3 | 3.63 | 1.32-9.99 | 0.01 | 2.36 | 0.71-7.84 | 0.16 |
| COPD (%) | 36 vs 18 | 2.48 | 1.45-4.25 | 0.01 | 1.02 | 0.36-2.84 | 0.97 |
| Cancer (%) | 8 vs 2 | 1.90 | 1.11-3.25 | 0.02 | 1.07 | 0.49-2.33 | 0.87 |
| EuroSCORE (points) | 34 ± 22 vs 22 ± 18 | 1.03 | 1.02-1.04 | &0.001 | 0.99 | 0.98-1.01 | 0.63 |
| ACEi/ARB (%) | 49 vs 66 | 0.48 | 0.28-0.81 | 0.006 | 0.56 | 0.31-1.01 | 0.08 |
| Beta-blockers (%) | 22 vs 37 | 0.48 | 0.26-0.88 | 0.02 | 0.57 | 0.29-1.15 | 0.12 |
AS = aortic stenosis; AVR = aortic valve replacement; COPD = chronic obstructive pulmonary disease; GFR = glomerular filtration rate; LV = left ventricular; NYHA = New York Heart Association.